Wall Street analysts expect Thermo Fisher Scientific to report Q1 2026 revenue of $10.87 billion and adjusted EPS of $5.27, with the current stock price of $467.35 trading well below the average target of $623.05.
The core metric investors are monitoring is organic revenue growth, which is anticipated to land around 1.2% as the company navigates the tail end of post-pandemic normalization.
Analysts are looking for stabilization in bioprocessing demand and signs that the 'funding winter' in the biotechnology sector is finally beginning to thaw. Furthermore, management’s outlook on China and the integration progress of the $9 billion Clario acquisition will be pivotal for maintaining the company's long-term growth algorithm.